Navigation Links
Valeant Grants Schering-Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal
Date:6/1/2009

ALISO VIEJO, Calif., June 1 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE: VRX) announced today that it has entered into an exclusive option agreement with Schering-Plough (NYSE: SGP) for taribavirin in Japan. In exchange for the exclusive option, Schering-Plough has agreed to waive and release its last right of refusal on taribavirin under a 2000 agreement, providing more flexibility for Valeant to actively pursue partnering arrangements for the rest of the world.

Under the terms of the option agreement, Valeant granted Schering-Plough the option to enter into an exclusive license agreement for the development and commercialization of taribavirin in Japan. Upon exercising the option and entering into the exclusive license agreement, Schering-Plough would provide a $2 million upfront payment to Valeant and pay mid-single digit royalties on net sales of taribavirin in Japan.

Taribavirin, a prodrug of ribavirin, is in Phase II development for the treatment of chronic hepatitis C in conjunction with a pegylated interferon.

"This agreement with Schering-Plough releases our company from the last right of refusal and provides us more flexibility to pursue partnering opportunities with other companies," said J. Michael Pearson, Valeant's chairman and chief executive officer. "With the data we have seen so far from the Phase IIb trial, we believe that taribavirin presents an attractive licensing opportunity."

About Taribavirin

Taribavirin is an investigational compound that has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory agency for the diagnosis, mitigation, treatment or cure of any disease or illness. It may not b
'/>"/>

SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
2. Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009
3. Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
4. Valeant Pharmaceuticals Announces Annual Stockholder Meeting Date
5. Valeant Pharmaceuticals to Present at Cowen and Company 29th Annual Health Care Conference
6. Valeant Pharmaceuticals Appoints President of Valeant Pharmaceuticals International
7. Valeant Pharmaceuticals to Announce 2009 First Quarter Results on May 5, 2009
8. Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting
9. Valeant Pharmaceuticals to Present at Bank of America and Merrill Lynch 2009 Health Care Conference
10. Valeant to Acquire Polish Dermatology Company
11. Valeant Announces Increase to Securities Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... of research suggesting a safe and effective role ... cancer, with fewer detrimental side effects and improved ... study will be published in final format today ... Endocrinology . , Breast cancer is the most ... States. Approximately 70% of breast cancers are diagnosed ...
(Date:7/23/2014)... July 23, 2014 Rich Dad® Education, a ... of their charity yard sale to support Habit for Humanity ... 100% of the proceeds will be donated to Habitat for ... are being donated to the Habitat for Humanity ReStore thrift ... 33903. , One of the highlights of the yard ...
(Date:7/23/2014)... York (PRWEB) July 23, 2014 Thousands ... to move forward in a federal multidistrict litigation underway ... Liebhard LLP reports. According to an Order dated July ... hospital’s bid for payment of a $1,000 fee for ... implant. , Among other things, the Order noted ...
(Date:7/23/2014)... better treating the pernicious disorders of obesity and dementia ... American University,s Center for Behavioral Neuroscience. In the paper, ... aimed at areas of the brain responsible for memory ... could play a role in reducing certain dementias., "In ... measures often fall short. This is a new way ...
(Date:7/23/2014)... Olympic gold medal-winning speed skater Chad ... Friday, July 18. Hedrick visited Roanoke as the special ... an Olympic-style event celebrating its 25th Anniversary in 2014. ... premier sponsor of the Commonwealth Games, which like Foot ... and all activity levels. , Hedrick, a native of ...
Breaking Medicine News(10 mins):Health News:Hormones after breast cancer: Not fuel for the fire after all? 2Health News:Hormones after breast cancer: Not fuel for the fire after all? 3Health News:Hormones after breast cancer: Not fuel for the fire after all? 4Health News:Hormones after breast cancer: Not fuel for the fire after all? 5Health News:Rich Dad Education Charity Yard Sale Raises Over $650 for Habitat for Humanity of Lee and Hendry Counties 2Health News:DePuy Pinnacle Hip Lawsuits Move Forward, as Federal Judge Denies Hospital Bid for $1000 Explant Fee, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Hip Lawsuits Move Forward, as Federal Judge Denies Hospital Bid for $1000 Explant Fee, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Hip Lawsuits Move Forward, as Federal Judge Denies Hospital Bid for $1000 Explant Fee, Bernstein Liebhard LLP Reports 4Health News:Targeting the brain to treat obesity 2Health News:Targeting the brain to treat obesity 3Health News:US Olympian Chad Hedrick Visits Foot Levelers 2
... , ... Care of Serious Illness is the first book to provide a comprehensive look at the ... E. Meier, Stephen L. Isaacs, Robert Hughes (Editors) , ... New York, NY (Vocus) April 1, 2010 -- Palliative Care: Transforming ...
... they know how cytomegalovirus continues to re-infect people , THURSDAY, ... how a virus known as cytomegalovirus (CMV), which infects up ... re-infects people again and again even though their immune systems ... always make people ill, but certain people, such as newborns ...
... SNM and the Radiological Society of North America (RSNA) ... at the Natcher Conference Center of the National Institutes ... workshop will focus on general issues of standardization to ... and analysis of images in clinical trials. The second ...
... beat vitamin B for those with scent-robbing viral infection, ... Acupuncture may help people who lose their sense of ... a new study, 15 patients with post-viral olfactory dysfunction ... acupuncture. These patients were compared with PVOD patients treated ...
... new study of brain activity in depressed and anxious people ... modified for better or for worse by anxiety. ... Behavioral Neuroscience , looked at depression and two types of ... panic; and anxious apprehension, better known as worry. The ...
... ... Mac platforms , ... Richardson, TX (PRWEB) April 1, 2010 -- Damaka, a technology pioneer in Mobile ... Real-time 2-way Video, Application Sharing) Sweeping™ between laptops and mobile devices earlier in May ...
Cached Medicine News:Health News:Palliative Care: Transforming the Care of Serious Illness 2Health News:Palliative Care: Transforming the Care of Serious Illness 3Health News:Demystifying a Common, Persistent Virus 2Health News:FDA, SNM and RSNA host April 13-14 two-topic imaging workshop 2Health News:Depressed? Fearful? It might help to worry, too 2Health News:Damaka Delivers Advanced Sweeping™ Capability of Live Sessions Across Multiple Devices Over WiFi, 3G and 4G Networks 2
(Date:7/23/2014)... and MOUNTAIN VIEW, Calif. , July ... leader in translational preclinical research, today unveiled their new ... signaling the transformation of Surpass, corporate culture to one ... our customers. This press release comes on the heels ... were added to the Silicon Valley Team:  David Craig, ...
(Date:7/23/2014)... 23, 2014 On Tuesday, July 1, ... suit in the 116 th Judicial District ... against RegenLab USA, LLC ("Defendant") for ... Relationships through false and misleading actions, fraud, ... Disparagement through libel, disparagement, defamation, misrepresentation, and ...
(Date:7/23/2014)... , July 23, 2014 /PRNewswire-iReach/ -- Use of Risk ... programs to delay generic market entry results in $5.4 ... new survey and analysis by economic consulting firm ... - http://photos.prnewswire.com/prnh/20140723/129680 Required by the ... and biologics, REMS programs are intended to improve drug ...
Breaking Medicine Technology:SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 2SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 3New Analysis Finds $5.4 Billion In Annual Lost Savings From Strategies Geared Toward Delaying Generic Drug Entry 2
... Inc ., a clinical-stage epigenetics oncology company, announced today ... with entinostat in combination and as a single agent ... San Antonio Breast Cancer Symposium ... phase 2 study of exemestane with and without entinostat ...
... MALVERN, Pa., Dec. 1, 2011 Auxilium Pharmaceuticals, Inc. ... today announced that the first patient has been dosed ... (collagenase clostridium histolyticum) for the treatment of idiopathic ... Shoulder syndrome. (Logo:  http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ...
Cached Medicine Technology:Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences 2Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences 3Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences 4Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences 5Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome 2Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome 3Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome 4Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome 5Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome 6
Full plate covers seal all 24 MicroAmp tubes...
96-Well PCR Plate Sealing Mat...
Easy to pierce, remove using foil stripper...
Inquire...
Medicine Products: